Celltrion Opens Up Canadian Market For Remsima SC

Launches Subcutaneous Version Of Biosimilar Infliximab Rival To Remicade

 
• By Dave Wallace

Celltrion has pushed into another new market with its Remsima SC subcutaneous version of infliximab, launching the innovative biosimilar in Canada.

Canada Flag Open Door
Celltrion’s launch opens up the Canadian market for Remsima SC • Source: Alamy

More from Biosimilars

More from Products